NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
Clinical Trials
3 trialsNCT00993239 2016-03-03
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
TetraLogic Pharmaceuticals
Phase 1 Completed
NCT01940172 2016-01-14
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
TetraLogic Pharmaceuticals
Phase 1 Completed